Erratum: Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation
verfasst von:
Mariana Toricelli, Fabiana H. M. Melo, Giovani B. Peres, Débora C. P. Silva, Miriam G. Jasiulionis
The authors declare that they have no competing interests.
Authors’ contributions
Conceived and designed the experiments: MT, FHMM, MGJ. Performed the experiments: MT, GBP. Analyzed the data: MT, FHMM, GBP, MGJ. Contributed reagents/materials/analysis: MT, FHMM, GBP, DCPS, MGJ. Wrote the paper: MT, FHMM, MGJ. All authors read and approved the final manuscript.
Erratum
After publication of this study [1], we found out that we unfortunately sent two figures in duplicate. They are Fig. 4b NT and Fig. 6c NT [1]. It is important to emphasize that the results shown in the graphs are correct since they represent the mean of three independent biological assays, each of them made in technical triplicates. The photographs are only representative figures of three biological assays.
Fig. 4
PI3-K signaling pathway is involved in anoikis resistance phenotype conferred by Timp1. The MaGFP and MaT1S cell lines were treated overnight with PI3-K inhibitors, Wortmannin (a) or LY294002 (b), and their clonogenic capability was evaluated. c Melan-a melanocytes stably transfected with GFP (control transfection, MaGFP) and Timp1 (MaT1S) were maintained in suspension for 1, 3, 5 and 24 hours. The Akt activation was assessed by Western blotting. *p < 0.05, **p < 0.01, ****p < 0.0001
Fig. 6
PI3-K inhibition renders melanoma cells anoikis sensitive. The 4C11- and 4C11+ melanoma cell lines were maintained in suspension for 96 hours in the presence of Wortmannin (a and b, respectively) or LY294002 (c and d, respectively). After 96 hours, suspended cells were plated and after 5 days clonogenic capacity was analyzed. 4C11-: non-metastatic melanoma cells; 4C11+: metastatic melanoma cells; NT: non-treated; Wn: Wortmannin; LY: LY294002. *p < 0.05, **p < 0.01, ***p < 0.001
×
×
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
The authors declare that they have no competing interests.
Authors’ contributions
Conceived and designed the experiments: MT, FHMM, MGJ. Performed the experiments: MT, GBP. Analyzed the data: MT, FHMM, GBP, MGJ. Contributed reagents/materials/analysis: MT, FHMM, GBP, DCPS, MGJ. Wrote the paper: MT, FHMM, MGJ. All authors read and approved the final manuscript.
Erratum: Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation
verfasst von
Mariana Toricelli Fabiana H. M. Melo Giovani B. Peres Débora C. P. Silva Miriam G. Jasiulionis
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.
Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.
Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
